Neuphoria Therapeutics (NEUP) Prepaid Assets (2023 - 2026)
Neuphoria Therapeutics' (NEUP) quarterly Prepaid Assets came in at $611913.0 in Q1 2026, up 2828.23% year-over-year from $20897.0 in Q1 2025, and up 2170.21% quarter-over-quarter from $26954.0 in Q4 2025.
Analysis
Neuphoria Therapeutics (NEUP) Prepaid Assets (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Prepaid Assets for 4 consecutive years, with $611913.0 the latest figure, recorded in Q1 2026.
- On a quarterly basis, Prepaid Assets rose 2828.23% year-over-year to $611913.0 in Q1 2026; TTM through Mar 2026 was $611913.0, a 2828.23% increase from a year earlier, with the FY2025 full-year figure at $740193.0, up 61.34% from the prior year.
- Prepaid Assets was $611913.0 for Q1 2026 at Neuphoria Therapeutics, up from $26954.0 in the prior quarter.
- Over five years, Prepaid Assets peaked at $797478.0 in Q2 2023 and troughed at $18469.0 in Q4 2024.
- A 4-year average of $347566.2 and a median of $231108.0 in 2024 frame the typical range for Prepaid Assets.
- Across the five-year window, Prepaid Assets sank 42.47% in 2024 and surged 2828.23% in 2026, its largest moves.
- Over 4 years, Prepaid Assets stood at $797478.0 in 2023, then slumped by 97.68% to $18469.0 in 2024, then soared by 45.94% to $26954.0 in 2025, then jumped by 2170.21% to $611913.0 in 2026.
- The last three Prepaid Assets figures came in at $611913.0 (Q1 2026), $26954.0 (Q4 2025), and $222319.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Neuphoria Therapeutics | 463.74 Mn | 444.30 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 611,913.00 |
| Dec 31, 2025 | 26,954.00 |
| Sep 30, 2025 | 222,319.00 |
| Jun 30, 2025 | 740,193.00 |
| Mar 31, 2025 | 20,897.00 |
| Dec 31, 2024 | 18,469.00 |
| Sep 30, 2024 | 231,108.00 |
| Jun 30, 2024 | 458,765.00 |
| Jun 30, 2023 | 797,478.00 |